Over the past week,
Regeneron Pharmaceuticals' (NasdaqGS:REGN) stock has faced a 10% drop, despite Dupixent's approval in Japan. Several leading financial institutions, including Alliancebernstein L.P., Atlas Capital Advisors Inc., and NEOS Investment Management LLC, have recently expanded their holdings in Regeneron. Still, some investors like Wellington Management Group LLP and Orion Portfolio Solutions LLC have shed their respective shares. Notably, Jim Cramer and many hedge funds are encouraging investment in Regeneron due to its current undervalued position. The company has also experienced several acquisitions and sales from major stakeholders, including Franklin Resources acquiring 149,124 shares and Norges Bank taking a $802.04 million position. Amidst all these, legal troubles face the firm as
investors sue over Eylea pricing practices. The company will be hosting a call and webcast to discuss Q1 2025 results on April 29, 2025. Overall, despite market shifts, lower price expectations, and analyst downgrades, the firm's
financial robustness and potential to bounce back make it a recommended buy by many analysts and investment groups.
Regeneron Pharmaceuticals REGN News Analytics from Fri, 07 Feb 2025 08:00:00 GMT to Sat, 05 Apr 2025 17:32:23 GMT -
Rating -2
- Innovation 4
- Information 7
- Rumor -3
